Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.91 |
| ▸ | HTR2C | P28335 | 19/20 | 0.91 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.91 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.91 |
| ▸ | DRD2 | P14416 | 3/20 | 0.73 |
| ▸ | DRD3 | P35462 | 3/20 | 0.73 |
| ▸ | HTR1A | P08908 | 2/20 | 0.73 |
| ▸ | DRD4 | P21917 | 2/20 | 0.73 |
| ▸ | HTR7 | P34969 | 2/20 | 0.73 |
| ▸ | HTR6 | P50406 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214328 | 0.95 | HTR2A (1.00) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL2216082 | 0.91 | HTR2A (0.90) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL2214914 | 0.90 | HTR2A (0.91) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL12441289 | 0.87 | HTR2A (0.90) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL12441254 | 0.87 | HTR2A (0.88) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL2214843 | 0.86 | HTR2A (0.88) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL2214331 | 0.86 | HTR2A (1.00) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL2215146 | 0.86 | HTR2A (1.00) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL2215659 | 0.84 | HTR2A (1.00) | HTR2AHTR2CSLC6A4KCNH2DRD2 | |
| SCHEMBL2214712 | 0.84 | HTR2A (0.81) | HTR2AHTR2CSLC6A4KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | claimed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | claimed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | claimed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | NPY5R, TPH2, MC5R | HTR2A 18/4885HTR2C 10/4885SLC6A4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.